Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Intra-Cellular Therapies is a biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule drugs targeting psychiatric and neurological disorders. Its portfolio includes FDA-approved products like CAPLYTA for schizophrenia and bipolar depression, with ongoing clinical trials for depression, bipolar disorder, autism-related irritability, and other CNS conditions. The company leverages proprietary technology platforms to develop innovative therapies addressing underserved markets.
This description was generated via AI from an annual report. Updated about 1 year ago.